Laura F. Newell

Hematology
3181 SW Sam Jackson Park Rd
Portland, OR 97239

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Attenuation of Immune Senescence Markers After Intensive Cancer Therapy Through Resistance Training: A Pilot Study.

Attenuation of Immune Senescence Markers After Intensive Cancer Therapy Through Resistance Training: A Pilot Study.

Journal: Cancers
Published: April 22, 2026

Performance of commonly used risk triage tools in predicting clinical deterioration among hospitalized hematopoietic stem cell transplant recipients.

Performance of commonly used risk triage tools in predicting clinical deterioration among hospitalized hematopoietic stem cell transplant recipients.

Journal: Haematologica
Published: August 06, 2025

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Journal: Blood neoplasia
Published: July 02, 2025

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202.

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202.

Journal: Blood vessels, thrombosis & hemostasis
Published: June 12, 2025

Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies.

Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies.

Journal: Cytotherapy
Published: May 24, 2025

Placental growth factor enhances inflammatory toll-like receptor responses in syncytiotrophoblasts.

Placental growth factor enhances inflammatory toll-like receptor responses in syncytiotrophoblasts.

Journal: Placenta
Published: January 15, 2025

CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.

CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.

Journal: Cancers
Published: January 05, 2024

A new beginning: can omidubicel emerge as the next, viable alternative donor source?

A new beginning: can omidubicel emerge as the next, viable alternative donor source?

Journal: Therapeutic advances in hematology
Published: March 10, 2023

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.

Journal: Blood advances
Published: September 26, 2022

Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates.

Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates.

Journal: Cytotherapy
Published: September 20, 2022

Acute GVHD: think before you treat.

Acute GVHD: think before you treat.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 10, 2021

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.

Journal: Blood advances
Published: October 28, 2021
Showing 1-12 of 40

Last Updated: 09/26/2026